Stock Track | iRadimed Stock Soars 7% on Strong Q3 Results and Raised Full-Year Guidance

Stock Track11-03

Shares of iRadimed Corporation (NASDAQ: IRMD), a leader in MRI-compatible medical devices, surged 7.08% in pre-market trading on Monday following the release of its third-quarter 2025 financial results and raised full-year guidance.

The company reported record revenue of $21.2 million for Q3, representing a 16% increase year-over-year and beating analyst expectations of $20.5 million. iRadimed's adjusted earnings per share (EPS) came in at $0.47, up 9% from the same period last year and slightly above the consensus estimate of $0.46.

Investors were particularly encouraged by iRadimed's decision to raise its full-year 2025 guidance. The company now expects revenue between $82.5 million and $83.5 million, up from its previous forecast of $80 million to $82.5 million. Additionally, iRadimed increased its GAAP diluted EPS guidance to a range of $1.68 to $1.72 for the full year.

Roger Susi, President and CEO of iRadimed, highlighted the company's seventeenth consecutive quarter of record revenue and noted that their pump and monitor backlog is at an all-time high. The company also announced it is on track to begin limited commercial shipments of its next-generation 3870 MRI-compatible IV infusion pump in December, with full U.S. commercialization expected in the first quarter of 2026.

The strong quarterly performance, raised guidance, and positive outlook for new product launches appear to be driving investor enthusiasm, resulting in the significant pre-market stock price increase for iRadimed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192458553?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192458553","market":"sg","top_or_hot":-1,"title":"Stock Track | iRadimed Stock Soars 7% on Strong Q3 Results and Raised Full-Year Guidance","media":"Stock Track","content":"<p>Shares of iRadimed Corporation (NASDAQ: IRMD), a leader in MRI-compatible medical devices, surged 7.08% in pre-market trading on Monday following the release of its third-quarter 2025 financial results and raised full-year guidance.</p>\n\n<p>The company reported record revenue of $21.2 million for Q3, representing a 16% increase year-over-year and beating analyst expectations of $20.5 million. iRadimed's adjusted earnings per share (EPS) came in at $0.47, up 9% from the same period last year and slightly above the consensus estimate of $0.46.</p>\n\n<p>Investors were particularly encouraged by iRadimed's decision to raise its full-year 2025 guidance. The company now expects revenue between $82.5 million and $83.5 million, up from its previous forecast of $80 million to $82.5 million. Additionally, iRadimed increased its GAAP diluted EPS guidance to a range of $1.68 to $1.72 for the full year.</p>\n\n<p>Roger Susi, President and CEO of iRadimed, highlighted the company's seventeenth consecutive quarter of record revenue and noted that their pump and monitor backlog is at an all-time high. The company also announced it is on track to begin limited commercial shipments of its next-generation 3870 MRI-compatible IV infusion pump in December, with full U.S. commercialization expected in the first quarter of 2026.</p>\n\n<p>The strong quarterly performance, raised guidance, and positive outlook for new product launches appear to be driving investor enthusiasm, resulting in the significant pre-market stock price increase for iRadimed.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | iRadimed Stock Soars 7% on Strong Q3 Results and Raised Full-Year Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | iRadimed Stock Soars 7% on Strong Q3 Results and Raised Full-Year Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-03 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of iRadimed Corporation (NASDAQ: IRMD), a leader in MRI-compatible medical devices, surged 7.08% in pre-market trading on Monday following the release of its third-quarter 2025 financial results and raised full-year guidance.</p>\n\n<p>The company reported record revenue of $21.2 million for Q3, representing a 16% increase year-over-year and beating analyst expectations of $20.5 million. iRadimed's adjusted earnings per share (EPS) came in at $0.47, up 9% from the same period last year and slightly above the consensus estimate of $0.46.</p>\n\n<p>Investors were particularly encouraged by iRadimed's decision to raise its full-year 2025 guidance. The company now expects revenue between $82.5 million and $83.5 million, up from its previous forecast of $80 million to $82.5 million. Additionally, iRadimed increased its GAAP diluted EPS guidance to a range of $1.68 to $1.72 for the full year.</p>\n\n<p>Roger Susi, President and CEO of iRadimed, highlighted the company's seventeenth consecutive quarter of record revenue and noted that their pump and monitor backlog is at an all-time high. The company also announced it is on track to begin limited commercial shipments of its next-generation 3870 MRI-compatible IV infusion pump in December, with full U.S. commercialization expected in the first quarter of 2026.</p>\n\n<p>The strong quarterly performance, raised guidance, and positive outlook for new product launches appear to be driving investor enthusiasm, resulting in the significant pre-market stock price increase for iRadimed.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRMD","symbol_name":"iRadimed Corporation","start_time":0,"source_url":"","article_id":"1192458553","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192458553","pubTimestamp":1762180339,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of iRadimed Corporation (NASDAQ: IRMD), a leader in MRI-compatible medical devices, surged 7.08% in pre-market trading on Monday following the release of its third-quarter 2025 financial...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRMD":"iRadimed Corporation"},"translate_title":"个股追踪|iRadimed股价飙升7%，第三季度业绩强劲，全年指引上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRMD":1},"content_text":"Shares of iRadimed Corporation (NASDAQ: IRMD), a leader in MRI-compatible medical devices, surged 7.08% in pre-market trading on Monday following the release of its third-quarter 2025 financial results and raised full-year guidance.\nThe company reported record revenue of $21.2 million for Q3, representing a 16% increase year-over-year and beating analyst expectations of $20.5 million. iRadimed's adjusted earnings per share (EPS) came in at $0.47, up 9% from the same period last year and slightly above the consensus estimate of $0.46.\nInvestors were particularly encouraged by iRadimed's decision to raise its full-year 2025 guidance. The company now expects revenue between $82.5 million and $83.5 million, up from its previous forecast of $80 million to $82.5 million. Additionally, iRadimed increased its GAAP diluted EPS guidance to a range of $1.68 to $1.72 for the full year.\nRoger Susi, President and CEO of iRadimed, highlighted the company's seventeenth consecutive quarter of record revenue and noted that their pump and monitor backlog is at an all-time high. The company also announced it is on track to begin limited commercial shipments of its next-generation 3870 MRI-compatible IV infusion pump in December, with full U.S. commercialization expected in the first quarter of 2026.\nThe strong quarterly performance, raised guidance, and positive outlook for new product launches appear to be driving investor enthusiasm, resulting in the significant pre-market stock price increase for iRadimed.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192458553","isCrawlerRequest":true}